MuyldermansGroup

Molecular imaging with macrophage CRIg-targeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis.

Zheng, F., Put S., Bouwens L., Lahoutte T., Matthys P., Muyldermans S., De Baetselier P., Devoogdt N., Raes G., and Schoonooghe S., "Molecular imaging with macrophage CRIg-targeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis.", J Nucl Med, vol. 55, issue 5, pp. 824-9, 2014 May.

Specific targeting of atherosclerotic plaques in ApoE(-/-) mice using a new Camelid sdAb binding the vulnerable plaque marker LOX-1.

De Vos, J., Mathijs I., Xavier C., Massa S., Wernery U., Bouwens L., Lahoutte T., Muyldermans S., and Devoogdt N., "Specific targeting of atherosclerotic plaques in ApoE(-/-) mice using a new Camelid sdAb binding the vulnerable plaque marker LOX-1.", Mol Imaging Biol, vol. 16, issue 5, pp. 690-8, 2014 Oct.

Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.

Evazalipour, M., D'huyvetter M., Tehrani B. Soltani, Abolhassani M., Omidfar K., Abdoli S., Arezumand R., Morovvati H., Lahoutte T., Muyldermans S., et al., "Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.", Contrast Media Mol Imaging, vol. 9, issue 3, pp. 211-20, 2014 May-Jun.

Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging.

Massa, S., Xavier C., De Vos J., Caveliers V., Lahoutte T., Muyldermans S., and Devoogdt N., "Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging.", Bioconjug Chem, vol. 25, issue 5, pp. 979-88, 2014 May 21.

Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.

Cardoso, F. Miguel, Ibañez L. Itatí, Van den Hoecke S., De Baets S., Smet A., Roose K., Schepens B., Descamps F. J., Fiers W., Muyldermans S., et al., "Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.", J Virol, vol. 88, issue 15, pp. 8278-96, 2014 Aug.

A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation.

Yardehnavi, N., Behdani M., Bagheri K. Pooshang, Mahmoodzadeh A., Khanahmad H., Shahbazzadeh D., Habibi-Anbouhi M., Ghassabeh G. Hassanzade, and Muyldermans S., "A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation.", FASEB J, 2014 Jun 2.

Pages

Subscribe to RSS - MuyldermansGroup